Abstracts tagged "pregnancy"

Abstract Number: 1716 • ACR Convergence 2021
Teratogenic Medication Use Associated with Favorable Odds of Contraception Counseling in a Cohort of Women with Systemic Lupus Erythematosus at a Large Tertiary Academic Medical Center
Shruti Chandramouli¹, Carolina Alvarez², R. Gina Silverstein³ and Saira Sheikh⁴, ¹Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Department of Obstetrics & Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, who have an increased risk of pregnancy complications such as preterm labor and preeclampsia,…
Abstract Number: 1249 • ACR Convergence 2020
The Impact of Anti-Ro Antibodies on the Pregnancy Outcome in Relation to Maternal Disease Presentation: A Descriptive Analysis of 231 Pregnancies
Eman Satti¹, Nawal Hadwan¹, Hadil Ashour¹, Rawan Saleh¹, Fiaz Alam¹, Omar Alsaed¹ and Samar Al Emadi¹, ¹Hamad medical corporation, DOHA, Qatar
Background/Purpose: Anti-Ro antibody positivity is linked to adverse fetal outcomes like congenital heart block CHB (2%) and neonatal lupus. The incidence of CHB increases to…
Abstract Number: 1770 • ACR Convergence 2020
Lupus Low Disease Activity State Protects Against Pre-Term Birth
Michelle Petri¹, Jessica Li² and Daniel Goldman³, ¹Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus low disease activity state (LLDAS) (Ann Rheum Dis. 2016;75:1615–21.) combine both low disease activity (SLEDAI score of ≤4, PGA >=1 no flare, no…
Abstract Number: 1257 • ACR Convergence 2020
Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
Sofia Gernaat¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Stanford Medicine, Stanford, CA, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Increased insulin resistance is pivotal in the development of gestational diabetes mellitus (GDM). Women with SLE may be at higher risk of GDM due…
Abstract Number: 1771 • ACR Convergence 2020
Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Review and Meta-analysis
Sabrina Hamroun¹, Aghilès Hamroun², Jean-Joël Bigna³, Frauke Foerger⁴, Edem Allado⁵ and Anna Molto¹, ¹Rheumatology Department, Cochin Hospital, Paris, Paris, France, ²Lille University, Faculty of Medicine, Lille, France, Lille, France, ³School of Public Health, Faculty of Medicine, University of Paris Sud XI, Le Kremlin-Bicêtre, France, Paris, France, ⁴University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland, ⁵Rheumatology Department, University Hospital of Nancy, France, Nancy, France
Background/Purpose: Women with spondyloarthritis (SpA) are often affected by the disease during their reproductive years1. However, little is known about the impact of the disease…
Abstract Number: 1323 • ACR Convergence 2020
Pregnancy in Axial Spondyloarthropathy: A Systematic Review & Meta-Analysis
Sinead Maguire¹, Tom O'Dwyer², Fiona Wilson³, David Mockler³ and Finbar O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²Independent Researcher, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis affecting the sacroiliac joints and the spine. Although this chronic condition affects a wide range of ages,…
Abstract Number: 1772 • ACR Convergence 2020
Vaccinations of Infants Born to Mothers on TNF Inhibitors: Safe Administration of Live-vaccines Given Per the National Immunization Program
Eman Satti¹, Nawal Hadwan¹ and Samar Al Emadi¹, ¹Hamad medical corporation, DOHA, Qatar
Background/Purpose: Biologic Disease-Modifying agents (bDMARDs) including TNF inhibitors are increasingly used during pregnancy over the last few decades for a variety of autoimmune conditions. Nevertheless,…
Abstract Number: 1324 • ACR Convergence 2020
Risk Factors for Adverse Pregnancy Outcomes in Women with Spondyloarthritis: An Observational Study from Two European Multidisciplinary Pregnancy Clinics
Ana Rita Cruz-Machado¹, Francesca Crisafulli², Sofia Barreira³, Patricia Martins⁴, Maria Chiara Gerardi⁵, Matteo Filippini², Micaela Fredi², Roberto Gorla⁶, Maria Grazia Lazzaroni², Cecilia Nalli⁶, Marco Taglietti², Andrea Lojacono⁷, Sonia Zatti⁸, Monica Centeno⁹, Cláudia Araújo¹⁰, Luísa Pinto¹⁰, Franco Franceschini¹¹, Angela Tincani¹², Susana Capela¹ and Laura Andreoli², ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁴Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universit�rio Lisboa Norte - Hospital de Santa Maria, Set�bal, Portugal, ⁵Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Milano, Italy, ⁶Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁸Obstetrics and Gynecology Unit, Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ⁹Departamento de Obstetrícia, Ginecologia e Medicina da Reprodução, Hospital de Santa Maria, CHULN, Lisbon, Portugal, ¹⁰Departamento de Obstetrícia, Ginecologia e Medicina da Reprodução, Hospital de Santa Maria, CHULN, Lisboa, Portugal, ¹¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Milano, Italy
Background/Purpose: Women with Spondyloarthritis (SpA) seem at increased risk for adverse pregnancy outcomes (APO), however limited data have been published so far. The aim of…
Abstract Number: 1773 • ACR Convergence 2020
Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
Christine Anastasiou¹, Laura Trupin¹, Patricia Katz², Zara Izadi³, Milena Gianfrancesco¹, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, Novato, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Atherton, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and…
Abstract Number: 1395 • ACR Convergence 2020
Poor Maternal and Fetal Outcome in Indian Women with Systemic Sclerosis: Interview-based Study at a Tertiary Center in India
Rajat Kharbanda¹, Naveen R², Durga P Misra², Latika Gupta³ and Vikas Agarwal⁴, ¹SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Post Graduate Institute of Medical Sciences, LUCKNOW, India
Background/Purpose: Poor obstetric outcomes have been described in Systemic sclerosis (SSc) in the developed world. We assessed effect of the disease in Indian women and…
Abstract Number: 1774 • ACR Convergence 2020
Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study
Nevena Rebic¹, Ria Garg², Sarah Munro², Glen Hazlewood³, Neda Amiri², Nick Bansback², Stephanie Ensworth², Corisande Baldwin⁴, Laurie Proulx⁵ and Mary De Vera¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴University of British Columbia, Calgary, AB, Canada, ⁵Canadian Arthritis Patient Alliance, Ottawa, Canada
Background/Purpose: Despite guidelines for managing rheumatoid arthritis (RA) in pregnancy, high rates of discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) considered safe for women with RA…
Abstract Number: 1446 • ACR Convergence 2020
Pregnancy Outcomes in Patients with Interstitial Lung Disease
Aardra Rajendran¹, Stephanie Giattino², Amanda Eudy³, Aparna Swaminathan⁴ and Megan Clowse⁵, ¹Duke University, Lewisville, NC, ²Duke University, Media, PA, ³Duke University, Durham, NC, ⁴Duke University, Durham, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Patients with interstitial lung disease (ILD) are often recommended to avoid conception or terminate pregnancy despite limited data on pregnancy outcomes and complications. Studies…
Abstract Number: 1775 • ACR Convergence 2020
Risk Factors for Adverse Pregnancy Outcomes of Women with Positive for Antiphospholipid Antibodies Treated with Conventional Therapies
Hiromi Shimada¹, Risa Wakiya², Mai Mahmound Fahmy Mansour¹, Shusaku Nakashima¹, Mikiya Kato¹, Koichi Sugihara¹, Yusuke Ushio¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, ²Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan, ³Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Antiphospholipid antibodies induce several obstetric complications including recurrent spontaneous abortion, preterm birth, intrauterine fetal death. EULAR recommendations for antiphospholipid syndrome (APS) indicates low dose…
Abstract Number: 0033 • ACR Convergence 2020
Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
Matthew Wright¹, Mette Kiel Smed², J Lee Nelson³, Jørn Olsen⁴, Merete Hetland⁵, Vibeke Zoffmann² and Damini Jawaheer⁶, ¹UCSF Children's Hospital Oakland Research Institute, Oakland, CA, ²The Juliane Marie Center, Copenhagen, Denmark, ³Fred Hutchinson Cancer Res Ctr and U of WA, Seattle, WA, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶UCSF Benioff Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…
Abstract Number: 1497 • ACR Convergence 2020
COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Bonnie Bermas¹, Megan Clowse², Milena Gianfrancesco³, Jonathan Hausmann⁴, Pedro M Machado⁵, Emily Sirotich⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹UTSouthwestern.edu, Dallas, TX, ²Duke University, Chapel Hill, NC, ³University of California, San Francisco, San Francisco, CA, ⁴Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁵University College London, London, United Kingdom, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant rheumatic disease patients reported to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].